Pathological biomarkers for Alzheimer's disease (AD) although effective, are not widely available due to issues in acquiring samples, lack of infrastructure, and high cost. In this context, researchers are trying to explore ocular biomarkers which can act as a direct window to cerebral pathology. This article gives an overview of the different ocular biomarkers for Alzheimer's disease explored so far, to help physicians detect this challenging disease in its early phase. Alzheimer's disease (AD) is a progressive neurodegenerative disease resulting in a severe cognitive loss, dementia, and eventual death.
At present physicians make a diagnosis of AD when patients exhibit early cognitive losses. Additionally, the diagnosis is finalized through mental state along with cognitive examinations, vascular, and neurological assessments to rule out other causes. However, the diagnosis can be…
